Observational Study
Copyright ©The Author(s) 2022.
World J Methodol. Sep 20, 2022; 12(5): 414-427
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.414
Table 1 General characteristics and responses of all subjects
Characteristics
Results (N = 175), n (%)
Gender Females: 88 (50.3)
Males: 87 (49.7)
Age (yr)Mean: 25.7 ± 4.1
GradeMedical student: 39 (22.3)
House officers: 74 (42.3)
Non-trainee medical officers: 17 (9.7)
Trainee medical officer: 38 (21.7)
Senior registrar: 4 (2.3)
Assist professor: 2 (1.1)
Professor: 1 (0.6)
Specialty of doctorsMedicine & allied: 98 (56)
Surgery & allied: 51 (29.1)
Others: 9 (5.1)
Not answered: 17 (9.7)
Do you have migraine? Yes: 22 (12.6)
No: 109 (62.3)
Maybe: 44 (25.1)
Confirmed migraine after reading the ICHD-3 criteria of all 3 types of migraineMigraine without aura: 36 (20.6)
Migraine with aura: 9 (5.1)
Chronic migraine: 3 (1.7)
No migraine: 127 (72.6)
Consulted any physicianGP: 19 (10.8)
Medical specialist: 22 (12.6)
Neurologist: 10 (5.7)
Ophthalmologist: 19 (10.8)
Other: 9 (5.1)
No consultation: 110 (62.8)
Physician able to diagnose migraineYes: 45 (25.7)
No: 9 (5.1)
Maybe: 9 (5.1)
Never consulted: 112 (64)
Knowledge of diagnostic criteria of migraineHeard and remember it: 66 (37.7)
Heard about it but don't remember: 85 (48.6)
Never heard about it: 24 (13.7)
Knowledge of prophylaxis of migraineI know its indications: 59 (33.7)
I knew its indications but don't remember: 70 (40)
Know only that it exists: 26 (14.8)
Don't know about it at all: 20 (11.4)
Aura is essential for migraine? Yes: 66 (37.7)
No: 83 (46.8)
Not sure: 26 (14.7)
Duration of standard prophylactic therapy of migraine?Do not know: 100 (57.1)
1 mo: 10 (5.7)
3 mo: 27 (15.4)
6 mo1: 24 (13.7)
12 mo: 14 (8)
Monthly headache rate for prophylaxis≥ 2 per mo: 64 (36.6)
≥ 3 per mo: 52 (29.7)
≥ 4 per mo1: 43 (24.6)
≥ 5 per mo: 15 (8.6)
Not available: 1 (0.6)
Used abortive (migraine patients only)Yes: 12 (25)
No: 34 (70.8)
Maybe: 2 (4.2)
Used prophylactic therapy (migraine patients only)Yes: 9 (18.7)
No: 38 (79.2)
Not sure: 1 (2.1)